Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Managing breakthrough pain (BTP) is important for many cancer patients because of the rapid onset and unpredictable nature of the pain episodes. Fentanyl buccal tablets (FBTs) are a rapid-onset opioid indicated for BTP management. However, FBT titration is needed to optimize BTP management. In this study, we aimed to evaluate the safety and efficacy of initiating 200 μg FBTs in Korean cancer patients. Methods: A retrospective analysis of medical records was performed on all advanced cancer patients treated with FBTs for BTP between October 2014 and July 2015. Patients who received initial doses of 200 μg FBTs for at least 3 days and cases in which FBT was available at doses of 200, 400, and 800 μg were included. Results: A total of 56 patients with a median age of 62 years (range, 32 to 80) were analyzed, 61% of whom were male. The median and mean values of morphine equivalent daily doses were 60 mg/day (range, 15 to 540) and 114.8 ± 124.8 mg/day, respectively. The most frequent effective doses of FBT were 200 μg (41 patients, 74%) and 400 μg (12 patients, 21%). Three patients (5%) could not tolerate 200 μg of FBT and discontinued treatment. Nausea, vomiting, somnolence, and dizziness were the most frequent treatment-related adverse events (AEs), and all AEs were grade 1 (mild) or 2 (moderate). Conclusions: FBT at the initial 200 μg dosage was well-tolerated and effective as a BTP management strategy in Korean cancer patients. Further prospective studies are needed to determine appropriate initiating doses of FBT in Korean patients with opioid tolerance.
Abstract
Background/Aims: Managing breakthrough pain (BTP) is important for many cancer patients because of the rapid onset and unpredictable nature of the pain episodes. Fentanyl buccal tablets (FBTs) are a rapid-onset opioid indicated for BTP management. However, FBT titration is needed to optimize BTP management. In this study, we aimed to evaluate the safety and efficacy of initiating 200 μg FBTs in Korean cancer patients. Methods: A retrospective analysis of medical records was performed on all advanced cancer patients treated with FBTs for BTP between October 2014 and July 2015. Patients who received initial doses of 200 μg FBTs for at least 3 days and cases in which FBT was available at doses of 200, 400, and 800 μg were included. Results: A total of 56 patients with a median age of 62 years (range, 32 to 80) were analyzed, 61% of whom were male. The median and mean values of morphine equivalent daily doses were 60 mg/day (range, 15 to 540) and 114.8 ± 124.8 mg/day, respectively. The most frequent effective doses of FBT were 200 μg (41 patients, 74%) and 400 μg (12 patients, 21%). Three patients (5%) could not tolerate 200 μg of FBT and discontinued treatment. Nausea, vomiting, somnolence, and dizziness were the most frequent treatment-related adverse events (AEs), and all AEs were grade 1 (mild) or 2 (moderate). Conclusions: FBT at the initial 200 μg dosage was well-tolerated and effective as a BTP management strategy in Korean cancer patients. Further prospective studies are needed to determine appropriate initiating doses of FBT in Korean patients with opioid tolerance.
참고문헌 (32)
- McCarthy EP, "Dying with cancer: patients' function, symptoms, and care preferences as death approaches", J Am Geriatr Soc, 48(5 Suppl), pp.S110~S121 (2000)[DOI]
- Mercadante S, "Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options", Curr Opin Anaesthesiol, 28, pp.559~564 (2015)[DOI]
- 서민석, "돌발성 암성 통증", Journal of Hospice and Palliative Care, 18(1), pp.1~8 (2015), 한국호스피스완화의료학회[DOI]
- Portenoy RK, "Breakthrough pain: definition, prevalence and characteristics", Pain, 41, pp.273~281 (1990)[DOI]
- Portenoy RK, "Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life", J Opioid Manag, 6, pp.109~116 (2010)[DOI]
- Zeppetella G, "Evidence-based treatment of cancer-related breakthrough pain with opioids", J Natl Compr Canc Netw, 11(Suppl 1), pp.S37~S43 (2013)[DOI]
- Jandhyala R, "Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials", J Pain Symptom Manage, 46, pp.573~580 (2013)[DOI]
- Messina J, "Fentanyl buccal tablet", Drugs Today (Barc), 44, pp.41~54 (2008)[DOI]
- Darwish M, "Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers", Clin Pharmacokinet, 44, pp.1279~1286 (2005)[DOI]
- Kleeberg UR, "Fentanyl buccal tablet for breakthrough cancer pain: why titrate?", Pain Pract, 11, pp.185~190 (2011)[DOI]
- Fine PG, "Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management", Pain Med, 11, pp.1024~1036 (2010)[DOI]
- [URL]
- Portenoy RK, "A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer", Clin J Pain, 22, pp.805~811 (2006)[DOI]
- 강정훈, "The efficacy of low-dose transdermal fentanyl in opioid-naive cancer patients with moderate-tosevere pain", The Korean Journal of Internal Medicine, 30(1), pp.88~95 (2015), 대한내과학회[DOI]
- Mercadante S, "Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose", J Pain Symptom Manage, 42, pp.464~469 (2011)[DOI]
- Mercadante S, "The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting", Support Care Cancer, 21, pp.2335~2339 (2013)[DOI]
- Mercadante S, "Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses", Curr Med Res Opin, 28, pp.963~968 (2012)[DOI]
- Kleeberg UR, "Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain", Eur J Pain, 19, pp.528~537 (2015)[DOI]
- Chlebowski RT, "Ethnicity and breast cancer: factors influencing differences in incidence and outcome", J Natl Cancer Inst, 97, pp.439~448 (2005)[DOI]
- WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)[DOI]
- Slatkin NE, "Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain", J Support Oncol, 5, pp.327~334 (2007)
- Weinstein SM, "Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study", Cancer, 115, pp.2571~2579 (2009)[DOI]
- Davies AN, "An observational study of oncology patients' utilization of breakthrough pain medication", J Pain Symptom Manage, 35, pp.406~411 (2008)[DOI]
- Ashburn MA, "The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain", Anesth Analg, 112, pp.693~702 (2011)[DOI]
- Takigawa C, "Breakthrough pain management using fentanyl buccal tablet (FBT) in combination with around-the-clock (ATC) opioids based on the efficacy and safety of FBT, and its relationship with ATC opioids: results from an open-label, multi-center study in Japanese cancer patients with detailed evaluation", Jpn J Clin Oncol, 45, pp.67~74 (2015)[DOI]
- 신성훈, "Clinical Usefulness of Hydromorphone-OROS in Improving Sleep Disturbances in Korean Cancer Patients: A Multicenter, Prospective, Open-Label Study", Cancer Research and Treatment, 46(4), pp.331~338 (2014), 대한암학회[DOI]
- Shibutani K, "Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients", Br J Anaesth, 95, pp.377~383 (2005)[DOI]
- Dahan A, "Sex-specific responses to opiates: animal and human studies", Anesth Analg, 107, pp.83~95 (2008)[DOI]
- Linnebur SA, "Pharmacy practice, research, education, and advocacy for older adults", Pharmacotherapy, 25, pp.1396~1430 (2005)[DOI]
- Chau DL, "Opiates and elderly: use and side effects", Clin Interv Aging, 3, pp.273~278 (2008)[DOI]
- Martin TL, "Fentanyl-related deaths in Ontario, Canada: toxicological findings and circumstances of death in 112 cases (2002-2004)", J Anal Toxicol, 30, pp.603~610 (2006)[DOI]
- 백선경, "A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting", Cancer Research and Treatment, 48(2), pp.768~774 (2016), 대한암학회